Discover 1,506 paid clinical trials in Loveland, Colorado. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,506
A Multi-Site Clinical Evaluation of the ARIES Norovirus Assay
for
Acute Gastroenteritis
Location: Aurora CO, Los Angeles CA, Indianapolis IN,
Sponsor: Luminex Corporation
Sex: All
Age: 0+
Code: NCT02092259
Recruiting
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
for
Acute Treatment of Migraine
Location: Aurora CO, Salt Lake City UT, Omaha NE, Kansas City KS,
Sponsor: Pfizer
Sex: All
Age: 6 - 17
Code: NCT04743141
Phase 3, Recruiting
The Pediatric Spine Foundation
for
Chest Wall and Spinal Disorders
Location: Aurora CO
Sponsor: University of Colorado, Denver
Sex: All
Age: 0 - 17
Code: NCT02540915
Recruiting
Longitudinal Study of Urea Cycle Disorders
for
Brain Diseases, Metabolic, Inborn,
Location: Aurora CO, Minneapolis MN, Los Angeles CA, Houston TX,
Sponsor: Andrea Gropman
Sex: All
Age: 0+
Code: NCT00237315
Recruiting
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
for
Hypogonadism, Male
Location: Aurora CO, Salt Lake City UT, Oklahoma City OK,
Sponsor: Halozyme Therapeutics
Sex: Male
Age: 12 - 17
Code: NCT06689085
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
for
Major Depressive Disorder
Location: Aurora CO, Chino CA, Philadelphia PA, Toronto,
Sponsor: Neurocrine Biosciences
Sex: All
Age: 18+
Code: NCT06963021
Phase 3, Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
for
Secondary Progressive Multiple Sclerosis (SPMS)
Location: Aurora CO, Albuquerque NM, Kansas City KS, Phoenix AZ,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 65
Code: NCT07225504
Phase 3, Recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
for
Congenital Adrenal Hyperplasia
Location: Aurora CO, Minneapolis MN, Dallas TX, San Francisco CA,
Sponsor: Neurocrine Switzerland GmbH
Sex: All
Age: 0 - 3
Code: NCT07536269
Phase 2, Recruiting
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer